← Back to all trials
Active Not Recruiting
NCT06845202
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Conditions: Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: Yes
Phase: PHASE1, PHASE2
Enrollment: 105
Sponsor: Alnylam Pharmaceuticals
Location: Clinical Trial Site Montclair California
Summary
The purpose of this study is to:
* evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324
* evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM
Eligibility Criteria
Inclusion Criteria:
Part A:
* Has a body mass index (BMI) of ≥27 kg/m\^2 and \
Source: ClinicalTrials.gov (NCT06845202). StuddyBuddy aggregates publicly available trial information.
